Literature DB >> 12800805

Endothelial binding of recombinant tissue plasminogen activator: quantification in vivo using a recirculatory model.

Michiel J Kemme1, Rik C Schoemaker, Jacobus Burggraaf, Monique van der Linden, Marina Noordzij, Matthijs Moerland, Cornelis Kluft, Adam F Cohen.   

Abstract

Binding of tissue plasminogen activator (t-PA) to the endothelium may be important in the prevention of thrombus formation. The aim was to develop a method to quantify endothelial binding in vivo. Nine healthy male volunteers received a 40 min continuous infusion with low dose recombinant t-PA (3.75 micrograms/min) and an indocycanine green infusion (0.5 mg/min) as control. A three-compartment recirculatory model was developed to account for non-specific circulatory delay effects. t-PA antigen, activity and t-PA/PAI-1 complex profiles showed a marked delay in increase at the beginning of the infusion. A reversible and concentration-dependent binding component was incorporated in the model which resulted in an accurate description of the t-PA concentration profile. t-PA binding was characterized by a dissociation constant of 5.9 ng/ml (SEM 1.8, CV 0%; fixed) and a binding capacity of 70 micrograms t-PA (SEM 10, CV 48%). This model can be used as a tool to quantify the ability of the endothelium to bind t-PA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12800805     DOI: 10.1023/a:1023293325245

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  37 in total

1.  The use of indocyanine green for the evaluation of hepatic function and blood flow in man.

Authors:  B D WIEGAND; S G KETTERER; E RAPAPORT
Journal:  Am J Dig Dis       Date:  1960-05

2.  Analysis of tissue-type plasminogen activator receptor (t-PAR) in human endothelial cells.

Authors:  H Fukao; O Matsuo
Journal:  Semin Thromb Hemost       Date:  1998       Impact factor: 4.180

3.  Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.

Authors:  J M van Griensven; R W Koster; J Burggraaf; L G Huisman; C Kluft; R Kroon; R C Schoemaker; A F Cohen
Journal:  Clin Pharmacol Ther       Date:  1998-01       Impact factor: 6.875

4.  Binding of tissue plasminogen activator to cultured human endothelial cells.

Authors:  K A Hajjar; N M Hamel; P C Harpel; R L Nachman
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

5.  Minimal compartmental model of circulatory mixing of indocyanine green.

Authors:  T K Henthorn; M J Avram; T C Krejcie; C A Shanks; A Asada; D A Kaczynski
Journal:  Am J Physiol       Date:  1992-03

6.  Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction.

Authors:  E Seifried; P Tanswell; D Ellbrück; W Haerer; A Schmidt
Journal:  Thromb Haemost       Date:  1989-06-30       Impact factor: 5.249

7.  Determination of blood volume using indocyanine green (cardio-green) dye.

Authors:  E C Bradley; J W Barr
Journal:  Life Sci       Date:  1968-09-01       Impact factor: 5.037

8.  Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor.

Authors:  K A Hajjar
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

9.  Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1).

Authors:  C Kluft; A F Jie; D C Rijken; J H Verheijen
Journal:  Thromb Haemost       Date:  1988-04-08       Impact factor: 5.249

10.  Binding of tissue plasminogen activator to endothelial cells. The effect on functional properties. Localization of a ligand in the B-chain of tPA.

Authors:  X F Cheng; M Brohlin; G Pohl; O Bäck; P Wallén
Journal:  Thromb Res       Date:  1995-01-15       Impact factor: 3.944

View more
  1 in total

1.  Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

Authors:  Donald E Mager; Wojciech Krzyzanski
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.